Bristol-Myers Squibb Co.
Bristol Myers Squibb (BMY)
Overview
Bristol Myers Squibb (BMS) is a global biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines and biologic therapies, with a portfolio spanning oncology, cardiovascular disease, immunology/inflammation, hematology, and neuroscience. Headquartered in Princeton, New Jersey (with major R&D operations in Lawrenceville and Summit, New Jersey, and additional global sites in California, Massachusetts, Spain, Belgium, Japan, and India), the company traces its history to Squibb Corporation (1858) and Bristol-Myers (1887), which merged in 1989. BMS is a large-cap pharmaceutical company generating roughly $49 billion in trailing annual revenue with around 32,500 employees worldwide; about 69% of its revenue is generated in the United States, and the company has been aggressively reshaping its portfolio through acquisitions to offset looming patent expirations on several of its largest legacy drugs.
What They Do & How They Make Money
Bristol Myers Squibb makes money by researching, developing, manufacturing, and marketing prescription drugs — small-molecule pills, biologic injectables, and increasingly cell therapies (CAR-T) — that it sells to healthcare systems, pharmacies, hospitals, and patients, typically through wholesalers and pharmacy benefit managers, with pricing negotiated against insurers and government payers. Its revenue model depends on patent-protected exclusivity: BMS invests heavily in R&D and clinical trials to bring new drugs to market, and once approved, a drug can generate very high margins for the years it remains under patent protection, since manufacturing costs are typically a small fraction of the price charged. When a drug's patent expires, generic or biosimilar competitors enter and revenue for that product typically collapses within a few years — a dynamic known as a "patent cliff" that is currently a central challenge for BMS, as several of its largest products (including blockbuster anticoagulant Eliquis and cancer immunotherapy Opdivo) face loss of exclusivity later this decade. To manage this, BMS has pursued a strategy of large acquisitions to replenish its pipeline and diversify revenue beyond legacy blockbusters, including its transformative $74 billion purchase of Celgene in 2019 (which brought Revlimid, Pomalyst, and Reblozyl into the portfolio) and more recent deals — Karuna Therapeutics ($14 billion, 2024, for schizophrenia drug Cobenfy/KarXT), Mirati Therapeutics (~$4.8 billion, 2024, oncology), and RayzeBio (~$4.1 billion, 2024, radiopharmaceuticals).
Business Segments
Bristol Myers Squibb operates and reports as a single biopharmaceutical business segment rather than dividing its financials into multiple reporting segments, reflecting how tightly its R&D, manufacturing, and commercial operations are integrated across therapeutic areas. Within that single segment, the company's revenue is concentrated in a relatively small number of major products and therapeutic franchises:
- Cardiovascular: Eliquis (apixaban), an oral anticoagulant co-marketed with Pfizer, is BMS's single largest product, representing roughly 30% of total revenue; the company also markets legacy product Plavix (clopidogrel).
- Oncology: Opdivo (nivolumab), an immuno-oncology checkpoint inhibitor, is the second-largest product at roughly 21% of revenue, alongside Yervoy (ipilimumab, ~6%) and newer oncology assets gained through the Mirati and RayzeBio acquisitions.
- Hematology: Revlimid (lenalidomide, ~6%) and Pomalyst/Imnovid (pomalidomide, ~6%), both gained through the Celgene acquisition, along with Reblozyl (luspatercept, ~5%) for certain anemias, and cell therapies Breyanzi and Abecma for blood cancers.
- Immunology: Orencia (abatacept, ~8%) for rheumatoid arthritis and other autoimmune conditions, along with newer immunology drug Sotyktu (deucravacitinib) for psoriasis.
- Neuroscience: Camzyos (mavacamten) for hypertrophic cardiomyopathy, and Cobenfy (KarXT), approved in September 2024 as the first novel mechanism-of-action treatment for schizophrenia in roughly 70 years, gained through the Karuna acquisition.
Competitors
- Broad pharmaceutical competitors: Pfizer, Merck, AbbVie, Eli Lilly, Johnson & Johnson, Novartis, Roche, and Gilead Sciences all compete with BMS across one or more of its therapeutic areas and are similarly navigating their own patent-cliff and pipeline-replenishment challenges.
- Oncology: Merck's Keytruda is Opdivo's chief rival in the immuno-oncology checkpoint-inhibitor market and has substantially outsold Opdivo in recent years; Roche and AstraZeneca also compete heavily in oncology.
- Cardiovascular: Johnson & Johnson/Bayer's Xarelto is the primary direct competitor to Eliquis in the oral anticoagulant market.
- Immunology: AbbVie (Humira, Skyrizi, Rinvoq) and Johnson & Johnson are dominant competitors in autoimmune/inflammatory disease treatment.
- Generics/biosimilars: As BMS's key products lose patent protection, generic manufacturers (e.g., Teva Pharmaceutical Industries) and biosimilar makers become direct competitive threats to legacy revenue.
Competitive Position
Bristol Myers Squibb's competitive strengths include a large, diversified portfolio of approved therapies across major disease areas, strong commercial execution and payer relationships built over decades, and a demonstrated willingness to use M&A aggressively to acquire new growth drivers rather than relying solely on internal R&D — a strategy that has repeatedly reshaped its revenue base (most dramatically through the Celgene deal). Its newer growth products — Cobenfy in neuroscience, Camzyos in cardiovascular, Breyanzi and Reblozyl in hematology, and its expanding radiopharmaceutical and oncology pipeline from Mirati and RayzeBio — represent the company's effort to build a "next generation" portfolio that can offset declines from its patent-expiring blockbusters. However, BMS faces significant structural headwinds: Eliquis and Opdivo, together representing roughly half of total revenue, both face loss of exclusivity later in the decade, and analysts have flagged an expected multi-year period of revenue and earnings pressure as a result — some forecasts point to mid-single-digit percentage annual revenue declines and high-single-digit percentage annual earnings declines over the next few years as this patent cliff plays out. The company also carries a relatively high debt load (elevated net debt-to-equity, reflecting its large acquisition spending), faces ongoing litigation overhang including a revived $6.7 billion lawsuit tied to Celgene merger-related contingent value rights, and — like all large pharmaceutical companies — is exposed to U.S. drug-pricing policy risk, including Medicare price negotiation under the Inflation Reduction Act. BMS's ability to scale its newer drugs fast enough to offset the coming Eliquis/Opdivo declines is the central question shaping its competitive trajectory over the next several years.